(-0.04%) 5 431.60 points
(-0.15%) 38 589 points
(0.12%) 17 689 points
(-0.17%) $78.49
(-2.47%) $2.89
(1.31%) $2 348.40
(1.91%) $29.62
(0.90%) $963.20
(0.31%) $0.934
(0.26%) $10.67
(0.59%) $0.788
(1.77%) $89.43
-4.63% $ 0.410
Live Chart Being Loaded With Signals
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer...
Stats | |
---|---|
Dzisiejszy wolumen | 10 334 |
Średni wolumen | 46 588 |
Kapitalizacja rynkowa | 1.99M |
EPS | $-2.28 ( Q1 | 2024-05-15 ) |
Następna data zysków | ( $-2.07 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0.0100 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0200 (4.88%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-08 | Goldman Sachs Group Inc | Sell | 72 874 | Common Stock |
2023-11-07 | Goldman Sachs Group Inc | Buy | 0 | Common Stock |
2023-09-12 | Jacob Jeffrey E. | Sell | 275 | Common Stock |
2023-03-27 | Simpson Jennifer K. | Buy | 99 383 | Stock Option (right to buy) |
2023-03-27 | Horvath Susan | Buy | 34 369 | Stock Option (right to buy) |
INSIDER POWER |
---|
62.71 |
Last 76 transactions |
Buy: 2 117 070 | Sell: 358 529 |
Panbela Therapeutics, Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Panbela Therapeutics, Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-25.65M (0.00 %) |
EPS: | $-232 430 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-25.65M (0.00 %) |
EPS: | $-232 430 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-35.73M (0.00 %) |
EPS: | $-40 749 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-34.62 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Panbela Therapeutics,
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej